Current approaches for risk stratification of infectious complications in pediatric oncology

被引:28
作者
Haertel, Christoph
Deuster, Maresa
Lehrnbecher, Thomas
Schultz, Christian
机构
[1] Univ Lubeck, Dept Pediat Hematol Oncol & Immunol, Childrens Hosp, Lubeck, Germany
[2] Goethe Univ Frankfurt, Dept Pediat Hematol & Oncol, D-6000 Frankfurt, Germany
关键词
cancer; children; febrile neutropenia; genetic susceptibility; infectious complications; risk stratification;
D O I
10.1002/pbc.21205
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Infections are serious complications of cytoreductive therapy in pediatric cancer patients presenting with febrile neutropenia. It is standard of care to initiate empirical intravenous broad-spectrum antibiotics until the fever and neutropenia resolve. However, it might be effective and safe to allow for early hospital discharge in certain subgroups of patients. Two strategies for risk stratification of pediatric cancer patients with regard to infectious complications are discussed in this review: (I) clinical risk parameters and laboratory measures to assist therapeutic management at presentation with fever in neutropenia, and (2) investigations of individual genetic susceptibility factors to tailor potential prophylactic approaches. Given the data available from a significant number of small studies, a large prospective non-inferiority trial is essential to assess low-risk clinical factors and additional laboratory or genetic markers for their predictive value. Pediatr Blood Cancer 2007;49:767-773. (c) 2007 Wiley-Liss, Inc.
引用
收藏
页码:767 / 773
页数:7
相关论文
共 70 条
[1]
Interleukin 6, but not tumour necrosis factor-alpha, is a good predictor of severe infection in febrile neutropenic and non-neutropenic children with malignancy [J].
Abrahamsson, J ;
Pahlman, M ;
Mellander, L .
ACTA PAEDIATRICA, 1997, 86 (10) :1059-1064
[2]
Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer [J].
Alexander, SW ;
Wade, KC ;
Hibberd, PL ;
Parsons, SK .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (01) :38-42
[3]
Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care? [J].
Ammann, RA ;
Simon, A ;
de Bont, ESJM .
PEDIATRIC BLOOD & CANCER, 2005, 45 (03) :244-247
[4]
Predicting bacteremia in children with fever and chemotherapy-induced neutropenia [J].
Ammann, RA ;
Hirt, A ;
Lüthy, AR ;
Aebi, C .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (01) :61-67
[5]
Early discharge of low-risk febrile neutropenic children and adolescents with cancer [J].
Aquino, VM ;
Tkaczewski, I ;
Buchanan, GR .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) :74-78
[6]
Baorto EP, 2001, CANCER, V92, P909, DOI 10.1002/1097-0142(20010815)92:4<909::AID-CNCR1400>3.0.CO
[7]
2-H
[8]
Polymorphism of angiotensin converting enzyme is associated with severe circulatory compromise in febrile neutropenic children with cancer [J].
Bárdi, E ;
Jenei, C ;
Kiss, C .
PEDIATRIC BLOOD & CANCER, 2005, 45 (02) :217-221
[9]
BASH RO, 1994, CANCER, V74, P189, DOI 10.1002/1097-0142(19940701)74:1<189::AID-CNCR2820740130>3.0.CO
[10]
2-7